Alpha-V-dependent outside-in signaling is required for the regulation of CD44 surface expression, MMP-2 secretion, and cell migration by osteopontin in human melanoma cells

Experimental Cell Research

Volumn 312, Issue 12, 2006, Pages 2214-2230

  Samanna, V ^a   Wei, H ^a   Ego Osuala, D ^a   Chellaiah, M A ^a  

^a UNIVERSITY OF MARYLAND DENTAL SCHOOL   (United States)

Author keywords

CD44; Integrin v 3; Melanoma; Migration; MMP 2; Osteopontin; p130Cas; pp60c Src kinase

Indexed keywords

AMINO ACID; CD51 ANTIGEN; GELATINASE A; HERMES ANTIGEN; LIGAND; MATRIX METALLOPROTEINASE INHIBITOR; MONOCLONAL ANTIBODY; MUTANT PROTEIN; OSTEOPONTIN; PROTEIN KINASE P60; VITRONECTIN RECEPTOR;

AMINO ACID SEQUENCE; ANTIGEN EXPRESSION; ARTICLE; BETA CHAIN; CARCINOGENICITY; CELL MIGRATION; CELL MOTILITY; CELL SURFACE; CLINICAL OBSERVATION; CONTROLLED STUDY; CORRELATION ANALYSIS; CULTURE MEDIUM; ENZYME ACTIVITY; ENZYME RELEASE; GENE EXPRESSION REGULATION; GENE OVEREXPRESSION; GENETIC ASSOCIATION; GENETIC TRANSDUCTION; HUMAN; HUMAN CELL; IMMUNOREGULATION; MELANOMA CELL; PRIORITY JOURNAL; PROTEIN PROTEIN INTERACTION; SOLUBILITY;

EID: 33745253734     PISSN: 00144827     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.yexcr.2006.03.022     Document Type: Article

References (75)

1. Ruoslahti E. Integrins. J. Clin. Invest. 87 (1991) 1-5
2. Miyauchi A., Alvarez J., Greenfield R.M., Teti A., Grano M., Colucci S., Zambonin-Zallone A., Ross F.P., Teitelbaum S.L., Cheresh D., and Hruska K.A. Recognition of osteopontin and related peptides by alphavbeta3 integrin stimulates immediate cell signals in osteoclasts. J. Biol. Chem. 266 (1991) 20369-20374
3. Flores M.E., Norgard M., Heinegard D., Reinholt F.P., and Andersson G. RGD-directed attachment of isolated rat osteoclasts to osteopontin, bone sialoprotein, and fibronectin. Exp. Cell Res. 201 (1992) 526-530
4. Denhardt D.T., Giachelli C.M., and Rittling S.R. Role of osteopontin in cellular signaling and toxicant injury. Annu. Rev. Pharmacol. Toxicol. 41 (2001) 723-749
5. Sodek J., Ganss B., and McKee M.D. Osteopontin. Crit. Rev. Oral. Biol. Med. 11 (2000) 279-303
6. Weber G.F. The metastasis gene osteopontin: a candidate target for cancer therapy. Biochim. Biophys. Acta 1552 (2001) 61-85
7. Fisher J.L., Schmitt J.F., Howard M.L., Mackie P.S., Choong P.F., and Risbridger G.P. An in vivo model of prostate carcinoma growth and invasion in bone. Cell Tissue Res. 307 (2002) 337-345
8. Ye Q.H., Qin L.X., Forgues M., He P., Kim J.W., Peng A.C., Simon R., Li Y., Robles A.I., Chen Y., Ma Z.C., Wu Z.Q., Ye S.L., Liu Y.K., Tang Z.Y., and Wang X.W. Predicting hepatitis B virus-positive metastatic hepatocellular carcinomas using gene expression profiling and supervised machine learning. Nat. Med. 9 (2003) 416-423
9. Gao Y.F., Li X., Xie Q.X., Gui S.Y., Wang Y., Zhou Q., Li J.B., and Jiang X.P. Expressions of osteopontin and CD44v6 in hepatocellular carcinoma and their clinical significance. Zhonghua Ganzangbing Zazhi 13 (2005) 227-228
10. Nemoto H., Rittling S.R., Yoshitake H., Furuya K., Amagasa T., Tsuji K., Nifuji A., Denhardt D.T., and Noda M. Osteopontin deficiency reduces experimental tumor cell metastasis to bone and soft tissues. J. Bone Miner. Res. 16 (2001) 652-659
11. Zhou Y., Dai D.L., Martinka M., Su M., Zhang Y., Campos E.I., Dorocicz I., Tang L., Huntsman D., Nelson C., Ho V., and Li G. Osteopontin expression correlates with melanoma invasion. J. Invest Dermatol. 124 (2005) 1044-1052
12. Reinholt F.P., Hultenby K., Oldberg A., and Heinegard D. Osteopontin-A possible anchor of osteoclasts to bone. Proc. Natl. Acad. Sci. U. S. A. 87 (1990) 4473-4475
13. Chellaiah M., and Hruska K.A. Osteopontin stimulates gelsolin associated phosphoinositide levels and PtdIns 3-hydroxyl kinase. Mol. Biol. Cell 7 (1996) 743-753
14. v subunit. Endocrinology 137 (1996) 2432-2440
15. Hsu M.Y., Meier F., and Herlyn M. Melanoma development and progression: a conspiracy between tumor and host. Differentiation 70 (2002) 522-536
16. Felding-Habermann B., Mueller B.M., Romerdahl C.A., and Cheresh D.A. Involvement of integrin αV gene expression in human melanoma tumorigenicity. J. Clin. Invest. 89 (1992) 2018-2022
17. Yang Y., Dang D., Atakilit A., Schmidt B., Regezi J., Li X., Eisele D., Ellis D., and Ramos D.M. Specific alpha v integrin receptors modulate K1735 murine melanoma cell behavior. Biochem. Biophys. Res. Commun. 308 (2003) 814-819
18. vβ3 integrin in human melanoma cell invasion. Proc. Natl. Acad. Sci. U. S. A. 89 (1992) 1557-1561
19. Hofmann U.B., Westphal J.R., Waas E.T., Becker J.C., Ruiter D.J., and van Muijen G.N. Coexpression of integrin alpha(v)beta3 and matrix metalloproteinase-2 (MMP-2) coincides with MMP-2 activation: correlation with melanoma progression. J. Invest. Dermatol. 115 (2000) 625-632
20. Godefroy E., Moreau-Aubry A., Diez E., Dreno B., Jotereau F., and Guilloux Y. alpha v beta3-dependent cross-presentation of matrix metalloproteinase-2 by melanoma cells gives rise to a new tumor antigen. J Exp. Med. 202 (2005) 61-72
21. Lesley J., Hyman R., English N., Catterall J.B., and Turner G.A. CD44 in inflammation and metastasis. Glycoconj. J. 14 (1997) 611-622
22. Harrison G.M., Davies G., Martin T.A., Mason M.D., and Jiang W.G. The influence of CD44v3-v10 on adhesion, invasion and MMP-14 expression in prostate cancer cells. Oncol. Rep. 15 (2006) 199-206
23. Matsumura Y., and Tarin D. Significance of CD44 gene products for cancer diagnosis and disease evaluation. Lancet 340 (1992) 1053-1058
24. Hart I.R., Birch M., and Marshall J.F. Cell adhesion receptor expression during melanoma progression and metastasis. Cancer Metastasis Rev. 10 (1991) 115-128
25. Hofmann U.B., Westphal J.R., van Muijen G.N., and Ruiter D.J. Matrix metalloproteinases in human melanoma. J. Invest. Dermatol. 115 (2000) 337-344
26. Brooks P.C., Stromblad S., L.C.v.T.L. Sanders R.T., Aimes W.G., Stetler-Stevenson J.P., and Quigley D.A. Localization of matrix metalloproteinase MMP-2 to the surface of invasive cells by interaction with integrin alpha-v-beta-3. Cell 85 (1996) 683-693
27. Takahashi K., Eto H., and Tanabe K.K. Involvement of CD44 in matrix metalloproteinase-2 regulation in human melanoma cells. Int. J Cancer 80 (1999) 387-395
28. Yu Q., and Stamenkovic I. Localization of matrix metalloproteinase 9 to the cell surface provides a mechanism for CD44-mediated tumor invasion. Genes Dev. 13 (1999) 35-48
29. Bourguignon L.Y., Gunja-Smith Z., Iida N., Zhu H.B., Young L.J., Muller W.J., and Cardiff R.D. CD44v(3,8-10) is involved in cytoskeleton-mediated tumor cell migration and matrix metalloproteinase (MMP-9) association in metastatic breast cancer cells. J. Cell. Physiol. 176 (1998) 206-215
30. Zhang Y., Thant A.A., Machida K., Ichigotani Y., Naito Y., Hiraiwa Y., Senga T., Sohara Y., Matsuda S., and Hamaguchi M. Hyaluronan-CD44s signaling regulates matrix metalloproteinase-2 secretion in a human lung carcinoma cell line QG90. Cancer Res. 62 (2002) 3962-3965
31. Filardo E.J., and Cheresh D.A. The beta turn in the cytoplasmic tail of the integrin alphav subunit influences conformation and ligand binding of alphavbeta3. J. Biol. Chem. 269 (1994) 4641-4647
32. 1 integrin subunit in vitro. J. Cell. Biol. 111 (1990) 721-729
33. Leavesley D.I., Ferguson G.D., Wayner E.A., and Cheresh D.A. Requirement of the integrin beta3 subunit for carcinoma cell spreading or migration on vitronectin and fibrinogen. J. Cell Biol. 117 (1992) 1101-1109
34. Kiefer M.C., Bauer D.M., and Barr P.J. The cDNA and derived amino acid sequence for human osteopontin. Nucleic Acids Res. 17 (1989) 3306
35. Schaller M.D., Otey C.A., Hildebrand J.D., and Parsons J.T. Focal adhesion kinase and paxillin bind to peptides mimicking beta integrin cytoplasmic domains. J. Cell Biol. 130 (1995) 1181-1187
36. Chellaiah M., Fitzgerald C., Alvarez U., and Hruska K. C-src is required for stimulation of gelsolin associated PI3-K. J. Biol. Chem. 273 (1998) 11908-11916
37. Chellaiah M.A., Soga N., Swanson S., McAllister S., Alvarez U., Wang D., and Dowdy S.F. Rho-A is critical for osteoclast podosome organization, motility, and bone resorption. J. Biol. Chem. 275 (2000) 11993-12002
38. Laemmli U.K. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 227 (1970) 680-685
39. Chellaiah M.A., Kizer N., Biswas R., Alvarez U., Strauss-Schoenberger J., Rifas L., Rittling S.R., Denhardt D.T., and Hruska K.A. Osteopontin deficiency produces osteoclast dysfunction due to reduced CD44 surface expression. Mol. Biol. Cell 14 (2003) 173-189
40. Wozniak M., Fausto A., Carron C.P., Meyer D.M., and Hruska K.A. Mechanically strained cells of the osteoblast lineage organize their extracellular matrix through unique sites of alphavbeta3-integrin expression. J. Bone Miner. Res. 15 (2000) 1731-1745
41. Gehlsen K.R., Davis G.E., and Sriramarao P. Integrin expression in human melanoma cells with differing invasive and metastatic properties. Clin. Exp. Metastasis 10 (1992) 111-120
42. Takaishi K., Sasaki T., and Taka L. Cell motility assay and inhibition by Rho-GDP dissociation inhibitor. Methods Enzymol. 256 (1995) 336-347
43. Chellaiah M., Kizer N., Silva M., Alvarez U., Kwiatkowski D., and Hruska K.A. Gelsolin deficiency blocks podosome assembly and produces increased bone mass and strength. J. Cell Biol. 148 (2000) 665-678
44. Bossy B., Bossy-Wetzel E., and Reichardt L.F. Characterization of the integrin alpha 8 subunit: a new integrin beta 1-associated subunit, which is prominently expressed on axons and on cells in contact with basal laminae in chick embryos. EMBO J. 10 (1991) 2375-2385
45. Takada Y., Elices M.J., Crouse C., and Hemler M.E. The primary structure of the alpha 4 subunit of VLA-4: homology to other integrins and a possible cell-cell adhesion function. EMBO J. 8 (1989) 1361-1368
46. Poncz M., Eisman R., Heidenreich R., Silver S.M., Vilaire G., Surrey S., Schwartz E., and Bennett J.S. Structure of the platelet membrane glycoprotein IIb. Homology to the alpha subunits of the vitronectin and fibronectin membrane receptors. J. Biol. Chem. 262 (1987) 8476-8482
47. Gilmore A.P., and Burridge K. Regulation of vinculin binding to talin and actin by phosphatidyl- inositol-4-5-bisphosphate. Nature 381 (1996) 531-535
48. Giancotti F.G., and Ruoslahti E. Integrin signaling. Science 285 (1999) 1028-1032
49. Xu Y.P., Zhao X.Q., Sommer K., and Moubayed P. Correlation of matrix metalloproteinase-2, -9, tissue inhibitor-1 of matrix metalloproteinase and CD44 variant 6 in head and neck cancer metastasis. J. Zhejiang Univ. Sci. 4 (2003) 491-501
50. Weber G.F., Ashkar S., Glimcher M.J., and Cantor H. Receptor-ligand interaction between CD44 and osteopontin (Eta-1). Science 271 (1996) 509-512
51. Zohar R., Suzuki N., Suzuki K., Arora P., Glogauer M., McCulloch C.A., and Sodek J. Intracellular osteopontin is an integral component of the CD44-ERM complex involved in cell migration. J. Cell. Physiol. 184 (2000) 118-130
52. Bafetti L.M., Young T.N., Itoh Y., and Stack M.S. Intact vitronectin induces matrix metalloproteinase-2 and tissue inhibitor of metalloproteinases-2 expression and enhanced cellular invasion by melanoma cells. J Biol. Chem. 273 (1998) 143-149
53. O'Toole T.E., Mandelman D., Forsyth J., Shattil S.J., Plow E.F., and Ginsberg M.H. Modulation of the affinity of integrin alpha IIb beta 3 (GPIIb-IIIa) by the cytoplasmic domain of alpha IIb. Science 254 (1991) 845-847
54. Bauer J.S., Varner J., Schreiner E., Kornberg L., Nicholas R., and Juliano R.L. Functional role of the cytoplasmic domain of the integrin alpha5 subunit. J. Cell Biol. 122 (1993) 209-221
55. Chan B.M.C., Kassner P.D., Schiro J.A., Byers H.R., Kupper T.S., and Hemler M.E. Distinct cellular functions mediated by different VLA integrin alpha subunit cytoplasmic domains. Cell 68 (1992) 1051-1060
56. Vuori K., Hirai H., Aizawa S., and Ruoslahti E. Introduction of p130cas signaling complex formation upon integrin-mediated cell adhesion: a role for Src family kinases. Mol. Cell Biol. 16 (1996) 2606-2613
57. Wei L., Yang Y., Zhang X., and Yu Q. Cleavage of p130Cas in anoikis. J. Cell. Biochem. 91 (2004) 325-335
58. Filardo E.J., Brooks P.C., Deming S.L., Damsky C., and Cheresh D.A. Requirement of the NPXY motif in the integrin (3 subunit cytoplasmic tail for melanoma cell migration in vitro and in vivo. J. Cell Biol. 130 (1995) 441-450
59. Chellaiah M.A., and Hruska K.A. The integrin αvβ3 and CD44 regulate the actions of osteopontin on osteoclast motility. Calcif. Tissue Int. 72 (2002) 197-205
60. Denhardt D.T., and Guo X. Osteopontin: a protein with diverse functions. FASEB J. 7 (1993) 1475-1482
61. Weber G.F., Ashkar S., and Cantor H. Interaction between CD44 and osteopontin as a potential basis for metastasis formation. Proc. Assoc. Am. Physicians 109 (1997) 1-9
62. Naot D., Sionov R.V., and Ish-Shalo D. CD44: structure, function, and association with the malignant process. Adv. Cancer Res. 71 (1997) 241-319
63. Oates A.J., Barraclough R., and Rudland P.S. The role of osteopontin in tumorigenesis and metastasis. Invasion Metastasis 17 (1997) 1-15
64. Hirama M., Takahashi F., Takahashi K., Akutagawa S., Shimizu K., Soma S., Shimanuki Y., Nishio K., and Fukuchi Y. Osteopontin overproduced by tumor cells acts as a potent angiogenic factor contributing to tumor growth. Cancer Lett. 198 (2003) 107-117
65. Cook A.C., Tuck A.B., McCarthy S., Turner J.G., Irby R.B., Bloom G.C., Yeatman T.J., and Chambers A.F. Osteopontin induces multiple changes in gene expression that reflect the six "hallmarks of cancer" in a model of breast cancer progression. Mol. Carcinog. 43 (2005) 225-236
66. Gao Y.F., Li X., Xie Q.X., Gui S.Y., Wang Y., Zhou Q., Li J.B., and Jiang X.P. Expressions of osteopontin and CD44v6 in hepatocellular carcinoma and their clinical significance. Zhonghua Ganzangbing Zazhi 13 (2005) 227-228
67. Katagiri Y.U., Sleeman J., Fujii H., Herrlich P., Hotta H., Tanaka K., Chikuma S., Yagita H., Okumura K., Murakami M., Saiki I., Chambers A.F., and Uede T. CD44 variants but not CD44s cooperate with β1-containing integrins to permit cells to bind to osteopontin independently of arginine-glycine-aspartic acid, thereby stimulating cell motility and chemotaxis. Cancer Res. 59 (1999) 219-226
68. Chellaiah M.A., Biswas R.S., Rittling S.R., Denhardt D.T., and Hruska K.A. Rho-dependent Rho kinase activation increases CD44 surface expression and bone resorption in osteoclasts. J. Biol. Chem. 278 (2003) 29086-29097
69. Bourguignon L.Y., Zhu H., Shao L., Zhu D., and Chen Y.W. Rho-kinase (ROK) promotes CD44v(3,8-10)-ankyrin interaction and tumor cell migration in metastatic breast cancer cells. Cell Motil. Cytoskeleton 43 (1999) 269-287
70. Abecassis I., Olofsson B., Schmid M., Zalcman G., and Karniguian A. RhoA induces MMP-9 expression at CD44 lamellipodial focal complexes and promotes HMEC-1 cell invasion. Exp. Cell Res. 291 (2003) 363-376
71. Hofmann U.B., Westphal J.R., van Muijen G.N., and Ruiter D.J. Matrix metalloproteinases in human melanoma. J. Invest. Dermatol. 115 (2000) 337-344
72. Guo W., and Giancotti F.G. Integrin signalling during tumour progression. Nat. Rev. Mol. Cell Biol. 5 (2004) 816-826
73. Teti A., Farina A.R., Villanova I., Tiberio A., Tacconelli A., Sciortino G., Chambers A.F., Gulino A., and Mackay A.R. Activation of MMP-2 by human GCT23 giant cell tumour cells induced by osteopontin, bone sialoprotein and GRGDSP peptides is RGD and cell shape change dependent. Int. J. Cancer 77 (1998) 82-93
74. Spessotto P., Rossi F.M., Degan M., Di Francia R., Perris R., Colombatti A., and Gattei V. Hyaluronan-CD44 interaction hampers migration of osteoclast-like cells by down-regulating MMP-9. J. Cell Biol. 158 (2002) 1133-1144
75. Johnson C., and Galis Z.S. Matrix metalloproteinase-2 and -9 differentially regulate smooth muscle cell migration and cell-mediated collagen organization. Arterioscler., Thromb., Vasc. Biol. 24 (2004) 54-60